The American Thyroid Association (ATA) recommends fine-needle aspiration (FNA) biopsy of nodules measuring >1.5 cm with low-suspicion sonographic patterns or >1.0 cm with high/intermediate-suspicion features. Routine biopsy of nodules <1 cm is not recommended. However, despite these recommendations, subcentimeter nodules are often referred for FNA biopsy. METHODS: This was a retrospective chart review of consecutive thyroid FNAs during an 18-month period (1157 patients, 1491 nodules, 2016-2017) to evaluate age, sex, medical history, diagnoses, and follow-up.
INTRODUCTION
Thyroid nodules are common in the United States. Studies estimate that approximately 16 million individuals in the United States have a palpable nodule on physical examination, whereas up to 219 million have an ultrasound-detectable nodule. 1 The overwhelming majority of these nodules are benign and only 7% to 15% are malignant. 2 Because thyroid nodules are typically the initial sign of cancer, the primary goal in their management is to distinguish the malignant lesions from those that are benign.
Ultrasonography is the imaging modality of choice for assessing thyroid nodules. 3 Currently, sonographic findings such as location, composition echogenicity, margins, calcifications, shape, vascularity and size are assessed to assign malignancy risk according to the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules (Table 1) . 2 Fineneedle aspiration (FNA) also plays a pivotal role in the evaluation process, but its use needs to be selective, because indiscriminate FNA of all nodules, regardless of their size or appearance, is superfluous and may result in costly ancillary molecular studies or unnecessary surgery. [4] [5] [6] Indications for FNA should be based on ultrasonographic malignancy risk stratification alongside clinical risk factors. In 2015, the American College of Radiology (ACR) published the Thyroid Imaging, Reporting, and Data System (TI-RADS), 7 an "easy to apply," ultrasonographic, risk-stratification method in which points are assigned for the composition, echogenicity, shape, margin, and echogenic foci of a given nodule. The calculated sum of these points is then used to place a nodule into 1 of 5 malignancy-risk groups: benign (TR1), minimally suspicious (TR2), mildly suspicious (TR3), moderately suspicious (TR4), or highly suspicious for malignancy (TR5). This stratification is based on an analysis of more than 3000 proven thyroid nodules demonstrating that the cancer risk is 2% for TR1 and TR2 nodules, 5% for TR3 nodules, 5% to 20% for TR4 nodules, and 20% for TR5 nodules. 8 Biopsy recommendations are provided in this system such that TR1 and TR2 nodules are not aspirated. TR3, TR4, and TR5 nodules are biopsied if they measure 2.5, 1.5, and 1.0 cm, respectively. Similar to the American Thyroid Association (ATA) recommendations, FNA is generally not advocated for nodules that measure <1.0 cm. 2, 7 There is a caveat, however, that, under certain circumstances (ie, associated metastatic disease), biopsy of nodules measuring 5 to 9 mm that fall under risk category TR5 may be warranted.
Although routine FNA of nodules <1 cm is currently not advised under either the ATA or ACR TI-RADS guidelines, most institutions receive occasional requests for such aspirations. We hypothesize that many of these biopsies are benign and unnecessary. By implementing the ACR TI-RADS system, we sought to determine whether this approach could prevent a good portion of these benign FNAs. Here, we report our experience with aspirates from subcentimeter nodules with regard to reasons for biopsy, diagnoses according to The Bethesda System for Reporting Thyroid Cytology (TBSRTC), and sonographic appearance, specifically with regard to suspicion pattern, as determined by the new ACR TI-RADS criteria.
MATERIALS AND METHODS

Patient Selection
In this Institutional Review Board-approved study, a retrospective chart review was performed for consecutive thyroid FNAs during an 18-month period (1157 patients, 1491 nodules, 2016-2017). Radiographic information was used to identify 61 subcentimeter nodules (4%) from 57 patients. Patient age, sex, history, TBSRTC diagnosis, ultrasound findings, and follow-up were retrieved. All diagnoses were made based on TBSRTC. Ultrasound studies obtained before FNAs were available for 51 nodules and were re-reviewed by a radiologist subspecializing in thyroid ultrasonography.
ACR TI-RADS Scoring and Statistical Analysis
Fifty-one ultrasound studies were re-reviewed by a blinded, board-certified radiologist who has had 30 years of experience performing thyroid ultrasound. During this re-review, Cancer Cytopathology August 2018
TI-RADS for Small Thyroid Nodules/Weiss et al the ACR TI-RADS criteria were applied. According to the guidelines, the sonographic characteristics were scored as follows: For composition, cystic 5 0 points, spongiform 5 0 points, mixed cystic 5 1 point, and solid 5 2 points; for echogenicity, anechoic5 0 points, hyperechoic or isoechoic 5 1 point, hypoechoic 5 2 points, very hypoechoic 5 3 points, wider-than-tall shape 5 0 points, and taller-than-wide shape 5 3 points; for margins, smooth 5 0 points, ill-defined 5 0 points, lobulated or irregular 5 2 points, and extrathyroidal extension (ETE) 5 3 points; and, for echogenic foci, none or large comet-tail artifact 5 0 points, macrocalcifications 5 1 point, peripheral (rim) calcifications 5 2 points, and punctate echogenic foci 5 3 points ( Table 2 ). The following categories were assigned based on the calculated sums: TR1 indicates a point total of 1; TR2, a point total of 2; TR3, a point total of 3; TR4, a point total from 4 to 6; and TR5, a point total 7. High ACR TI-RADS scores included TR4 and TR5, an intermediate TI-RADS score was TR3, and low TI-RADS scores included TR1 and TR2. Statistical analyses were performed using 2-tailed Fisher exact tests.
RESULTS
Patient Characteristics
Over an 18-month period from 2016 to 2017, 1491 nodules from 1157 patients were aspirated. Ultrasounds were reviewed and identified 57 patients who had 61 subnodules measuring less < 1 cm. Forty percent of patients who had subcentimeter nodules in this study were under the care of an endocrine specialist. During the study period, 4% of the institution's thyroid FNAs were subcentimeter in size. Patients in the subcentimeter cohort had an average age of 52 years with an age range of 19-81 years. Forty-two patients were female, and 5 were male. The reasons for biopsy of these nodules included: biopsy because of a concomitant larger companion nodule (44%), a personal history of cancer (19%), a family history of cancer (9%), or a suspicious sonogram that included calcification and/or irregular contours (16%). In 14% of nodules, the indication was unclear. Twenty-five percent of patients were referred for biopsy from an outside institution. The average nodule size within the subcentimeter cohort was 7.8 mm, and the nodules ranged in size from 5 to 9 mm.
Subcentimeter Diagnoses
All nodules were interpreted using TBSRTC criteria. Diagnoses for the subcentimeter cohort were as follows: 69% benign (42 of 61 nodules), 10% PTC (6 of 61 nodules), and 15% atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) (9 of 61 nodules). Seven percent of nodules unsatisfactory/nondiagnostic (UNS/ND) (4 of 61 nodules) compared with a 3% ND rate for all sized nodules. Bethesda diagnoses for nodules <7 mm were as follows: 17% ND (2 of 12 nodules), 0% PTC (0 of 12 nodules) and 8% AUS/FLUS (1 of 12 nodules; this nodule was benign on follow-up FNA). Of the patients aged <55 years, 4 had a diagnosis of PTC (12%; 4 of 33 patients), and 4 had an interpretation of AUS/FLUS (12%; 4 of 33 patients). There were 2 PTCs (9%; 2 of 23 patients) and 5 interpretations of AUS/FLUS (22%; 5 of 23 patients) among patients aged 55 years.
Ultrasound Characteristics and ACR TI-RADS Scoring
Fifty-one patients with 61 subcentimeter thyroid nodules had ultrasound studies available for radiologic examination. The images from these patients were reviewed by a radiologist and scored according to ACR TI-RADS criteria (Table 3 , Fig. 1 ). Of the nodules with low TI-RADS scores (TR1/TR2), 2 were nondiagnostic/unsatisfactory (ND/ UNSAT), and 15 were benign. Intermediate TI-RADS scores (TR3) included 1 ND/UNSAT, 13 benign, and 3 AUS/FLUS interpretations. There were 9 benign, 3 AUS/ FLUS, and 5 PTCs with high TI-RADS scores (TR4/ TR5). High TI-RADS scores (TR4/TR5) were indicative of PTC in 29.4% of nodules (Table 4) , whereas no PTCs were detected in the low TI-RADS score (TR1/TR2) category (P < .01). High and intermediate TI-RADS scores (TR3 and TR4/TR5) were predictive of PTC/AUS/FLUS in 32% of nodules compared with 0% in those with low TI-RADS scores (P < .01).
Most of PTCs and all AUS/FLUS FNAs in this study had follow-up at our institution with resection or repeat FNA biopsy. However, most of the nodules with only a benign FNA interpretation had follow-up on ultrasound. In total, 10 of 61 nodules underwent resection, and 3 of 61 nodules underwent repeat FNA. Of the 10 nodules from patients who had surgical follow-up, 5 were from patients who had a diagnosis of PTC on FNA, 3 were from patients who had an AUS/FLUS FNA diagnosis, and 2 were from patients who had a benign FNA diagnosis. All 5 nodules with a PTC FNA diagnosis were confirmed as PTC on resection. Of the 3 patients who had AUS/FLUS FNAs, 1 had a PTC, 1 had a Hurthle cell adenomatoid nodule, and the other had a hyperplastic nodule upon resection. The 2 patients who had benign FNAs also had benign thyroid tissue after resection. For the 3 patients who underwent repeat FNAs for AUS/FLUS, 2 were diagnosed as benign on follow-up FNA, and 1 had a repeat AUS/FLUS diagnosis.
Of the 5 subcentimeter PTCs in this series in patients who had ultrasonography available, 3 were TR4 nodules and 2 were TR5 nodules on TI-RADS evaluation. Four of the 5 patients who had PTC FNAs with available ultrasonography underwent resection at our institution and had PTC confirmed. One nodule demonstrated minimal microscopic ETE, and another was metastatic to 2 of 4 regional lymph nodes. The ages of patients who had PTC at the time of diagnosis were 52, 57, 19, 50 (minimal ETE), and 42 (metastatic to lymph Figure 1 . Subcentimeter nodules from the current cohort with Thyroid Imaging, Reporting, and Data System (TI-RADS) scores of 1 through 5 reveal: TI-RADS 1, a cyst with a punctate echo consistent with colloid; TI-RADS 2, a nodule demonstrating an isoechoic, spongiform pattern; TI-RADS 3, an isoechoic solid nodule; TI-RADS 4, a predominantly solid, isoechoic nodule with peripheral calcifications; and TI-RADS 5, a nodule exhibiting marked hypoechogenicity with a taller-than-wide pattern. Cancer Cytopathology August 2018
TI-RADS for Small Thyroid Nodules/Weiss et al nodes) years. Of the 6 AUS/FLUS FNAs, 3 were resected (1 with TR3 and 2 with TR4 TI-RADS scores). One was identified as a Hurthle cell adenomatoid nodule (TR4), 1 was identified as nodular hyperplasia (TR3), and the other was identified as PTC (TR4). The latter nodule occurred in a man aged 28 years who had bilateral disease and a family history of PTC (a mother and a sister previously diagnosed with PTC). The 3 remaining AUS/ FLUS FNAs (2 TR3 and 1 TR4) had subsequent FNA biopsies: 1 was identified as AUS (TR3), and 2 were benign (TR4). The nodules with higher TI-RADS scores (TR4/TR5) had the following follow-up diagnoses: 35% PTC and 65% benign ( Fig. 2A) versus 0% PTC, 6% AUS/FLUS, 88% benign, and 6% ND/UNSAT for the intermediate TI-RADS group (Fig. 2B ).
DISCUSSION
The current study provides a correlation of sonographic features, as scored using the ACR TI-RADS criteria, with pathologic diagnoses in a cohort of subcentimeter thyroid nodules. We observed that, of nodules with higher TI-RADS scores (TR4/TR5) that were moderately and highly suspicious for malignancy, 35% were PTC, and 65% were benign. Lesions with intermediate TI-RADS scores corresponding to a low risk of malignancy (TR3) were benign in 88%, AUS/FLUS in 6%, and ND/UNSAT in 6% of nodules, respectively. Finally, of the nodules with low TI-RADS scores (TR1/TR2), consistent with colloid cysts or nodules that are not suspicious for malignancy, 88% were benign, and 12% were ND/UNSAT. All PTCs were discovered in nodules with higher TI-RADS scores. None of the TR1/TR2 lesions were malignant on aspiration. Following the TI-RADS guidelines, such nodules do not require biopsy or active surveillance. Therefore, our data support management based on the TI-RADS sonographic morphologic evaluation of these subcentimeter nodules. In our study, this approach would have prevented unnecessary aspirations in 34 of 51 patients (67%) who had TI-RADS scores of from TR1 to TR3, because no definite malignant nodules or nodules that were suspicious for malignancy were identified in this group (only 1 AUS/FLUS TR3 nodule was identified in these categories, and that nodule had AUS diagnosed again on follow-up FNA biopsy).
Our results do not provide definitive evidence for biopsy over active surveillance of subcentimeter nodules with high TI-RADS scores, because there is now support for surveillance of subcentimeter indolent papillary carcinomas. [9] [10] [11] The majority of TR4/TR5 TI-RADS nodules in our series were benign (65%), endorsing the clinical management of subcentimeter TR4/TR5 nodules. However, of the 5 subcentimeter PTCs with high TI-RADS scores (or papillary microcarcinomas, as they are often classified) identified within this study, 1 was bilateral (TR4), 1 had microscopic but no gross ETE (TR5), and 1 had regional lymph node metastases (TR4). Although these 3 tumors (6%; 3 of 51 nodules) could be considered slightly more aggressive, none of these features were detected at the time of ultrasound, and none are suspected to significantly decrease the patient's life expectancy. In the new eighth edition of the American Joint Committee on Cancer (AJCC) thyroid cancer staging system, regional lymph node metastases and microscopic ETE were removed from T3 disease. In addition, the age cutoff used for staging was increased from 45 years to 55 years. These changes in the eighth edition are based on data suggesting that regional lymph node metastases (as in our patient aged 42 years) and microscopic ETE without gross ETE (as in our patient aged 50 years) are not unfavorable prognostic factors. Although we do not have long-term follow-up on these patients, both would have stage I disease. These data suggest that, whereas these patients may be at increased risk of recurrent disease, the microscopic ETE and regional lymph node metastases in young patients (aged <55 years) have only a minor impact on survival (98%-100% expected 10-year disease-specific survival). 12, 13 Other investigators have analyzed the utility of ultrasound imaging for the stratification of malignancy risk. A study by Sharma et al, who also restricted their investigation to nodules <1 cm, evaluated the accuracy of various ultrasound features in predicting malignancy among 104 patients who had 108 subcentimeter nodules. Although the TI-RADS scoring system was not used, those authors discovered that certain suspicious ultrasound characteristics were helpful in judging the likelihood of malignancy. However, their study was inherently biased, because these nodules were concerning enough to the patient and/or clinician that they presented for biopsy. 14 Gweon et al assessed the role of ultrasound for predicting malignancy in indeterminate thyroid nodules that ranged in size from 2 to 62 mm, with 44.5% measuring < 1 cm. By using various sonographic features, the nodules were placed into 1 of 3 categories: probably benign, low suspicion for malignancy, and suspicious for malignancy. 15 The authors concluded that nodules deemed suspicious for malignancy are likely to be malignant, and these patients might be referred directly to surgery rather than undergoing repeat FNA. Kamaya et al also examined ultrasonographic scoring of indeterminate thyroid nodules, applying earlier versions of the TI-RADS system (Park et al and Kwak et al 17 
)
Those authors demonstrated that a score of 4 on both the Park et al and Kwak et al systems (1 or 2 suspicious sonographic features of malignancy, including 1 of the following: hypoechoic, microcalcifications, noncircumscribed margin, lymph node abnormality) indicates good separation between benign and malignant. 18 Although the average nodule measured 22 mm, lesions as small as 7 mm were included. Kamaya and colleagues also demonstrated that TI-RADS had good predictive power, with an area under the receiver operating characteristic curve of 0.827. The authors suggested that careful sonographic evaluation could be an accurate and cost-effective method for assessing the risk of malignancy in indeterminate nodules. Our current TI-RADS study on subcentimeter nodules has some inherent limitations. There may have been an inherent selection bias toward patients who had clinical risk factors and/or nodules with worrisome radiographic features. Of the 6 patients with PTC in this cohort, 2 had concomitant larger thyroid nodules, and 3 reported personal or family histories of carcinoma. All 6 had concerning ultrasound studies, as evidenced by the high TI-RADS scores. There were likely many other subcentimeter nodules identified during the study period that did not warrant biopsy. An additional limitation of this study is the evaluation of a small cohort of 51 subcentimeter nodules. The restriction of our review to nodules smaller than 1 cm limited our sample size. Another limitation that has also been cited in prior TI-RADS investigations is that the experience of our academically centered radiologist and associated comfort level with the TI-RADS scoring system may not be representative of a community radiologist. This factor may inflate the impact of the TI-RADS scoring system in the evaluation of subcentimeter nodules. Finally, there is a technical limitation to FNAs of small sized thyroid nodules, because there is the possibility that surrounding benign tissue may be sampled during the FNA rather than the actual lesion. This sampling error could lead to falsenegative findings after FNA for lesions with more concerning ultrasonographic features.
Currently, TBSRTC does not integrate ultrasonographic findings into the recommended management guidelines. We examined the utility of the updated ACR TI-RADS scoring system for evaluating the malignancy potential of subcentimeter nodules. Our study indicates that such radiographic assessment can be highly predictive of the pathologic diagnosis and potentially may guide management. This finding is in agreement with 2 previous studies by Yang et al and You et al on the sonographic appearance of follicular variants of papillary thyroid carcinoma. 19, 20 None of the nodules with TI-RADS scores from TR1 to TR3 were malignant in our cohort. According to TI-RADS recommendations, nodules do not require biopsy or surveillance unless a score of TR3 is obtained.
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TI-RADS for Small Thyroid Nodules/Weiss et al Under these circumstances, biopsy would be recommended for nodules <2.5 cm in greatest dimension and surveillance would be recommended for nodules >1.5 cm in greatest dimension. Triaging lesions in this manner will allow the more accurate selection of nodules for biopsy and ultimately reduce the number of FNAs performed on benign lesions.
In conclusion, our data provide evidence to validate use of the TI-RADS scoring system for the characterization and stratification of malignancy risk of subcentimeter thyroid nodules and support the management of lesions with ACR TI-RADS scores of TR1/TR3 without biopsy intervention. However, this approach will need to be confirmed in larger, prospective studies. Similarly, improved methods for determining which subcentimeter, high-scoring TI-RADS nodules warrant biopsy will need to be explored. Certainly, in the current era of overdiagnosis and overtreatment of indolent thyroid cancers, caution should be taken to avoid recommendations of biopsy for universally small, and mostly indolent, tumors.
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